Condition: Patellofemoral Osteoarthritis · Sponsor: University Hospital, Basel, Switzerland
The purpose of this investigator-initiated study is to assess the efficacy of treating patellofemoral osteoarthritis with an Advanced Therapy Medicinal Product (ATMP), autologous nasal chondrocyte tissue engineered cartilage (N-TEC), in comparison with a standard therapy using platelet rich plasma injections. The engineered cartilage graft is obtained by culturing expanded autologous nasal chondrocytes within a collagen type I/III membrane.
This description comes directly from the study's public registry record.
Marcus Mumme, Dr · 0041615565885 · marcus.mumme@usb.ch
Always discuss trial participation with your own doctor first.
| Poliklinika Ivković | Zagreb, Croatia | Recruiting |
| Poliklinika Ortho Plus | Zagreb, Croatia | Recruiting |
| Universitätsklinikum Freiburg | Freiburg im Breisgau, Germany | Not Yet Recruiting |
| Orthopädische Klinik König-Ludwig-Haus | Würzburg, Germany | Not Yet Recruiting |
| University Hospital Basel | Basel, Switzerland | Recruiting |
| Crossklinik | Basel, Switzerland | Recruiting |
| Hôpitaux universitaires de Genève | Geneva, Switzerland | Recruiting |
| Ospedale Regionale di Lugano | Lugano, Switzerland | Recruiting |
| Sportclinic, Klinik Hirslanden | Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06163573